RECRUITING

Geriatric Assessment and Technology Evaluation in Prostate Cancer

Conditions

Prostate Cancer Prostate Cancer Metastatic

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

By doing this study, doctors hope to learn more about factors that contribute to frailty (a condition where older adults feel weak, get tired easily, and struggle more with everyday activities) and serious side effects among men over the age of 65 who will receive androgen deprivation therapy (also called "hormone therapy") for prostate cancer that has spread to other parts of their body. Participation in this research will last about 5 years. For the first year, participants will have 5 study visits where they have give blood samples, answer survey questions, and use a wearable device. After study visits are complete, there is a 4-year follow-up period. Research team will check regular doctor visits and look at participants' medical records.

Official Title

Prostate Cancer Geriatric Assessment and Technology Evaluation (ProsGATE) Study

Quick Facts

Study Start:2026-04

Study Completion:2031-04

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06215508

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Minutes

Sexes Eligible for Study:MALE

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Patients must have histologically or cytologically confirmed adenocarcinoma of prostatic origin without neuroendocrine differentiation or signet ring or small-cell histologic features. * Patients must be metastatic by having at least one metastatic lesion seen at the time of diagnosis or upon initiation of treatment on bone scan or computed tomography (CT) or magnetic resonance imaging (MRI), or by next-generation molecular imaging (FDG, F-18 sodium fluoride (NaF), C-11 choline, F-18 Fluciclovine, Ga-68 Prostate-specific membrane antigen (PSMA-11) positron emission tomography/computed tomography or magnetic resonance imaging. * Age ≥ 65years. positron emission tomography the aforementioned GA tools are only validated in those aged 65 and older. * Planned initiation of intensified hormone deprivation (ADT and ARSI) * Ability to understand and the willingness to sign a written informed consent document.	* Participants with previous exposure to ADT/ARSI within 12 months of diagnosis, except those who initiated ADT/ARSI within 12 weeks of enrollment. * Participants who had surgical orchiectomy outside of 12 weeks before their metastatic diagnosis. * Participants who have had previous chemotherapy for metastatic prostate cancer. * Uncontrolled intercurrent illness. "Uncontrolled intercurrent illness" refers to a concurrent medical condition that is not adequately managed or stable at the time of enrollment. This could be any illness, disorder, or medical issue occurring alongside the primary disease being treated or studied, and its lack of control poses additional risk to the patient or complicates the management of the primary condition. For example, in the context of enrolling patients in a clinical trial for a cancer treatment, a patient with uncontrolled diabetes mellitus or hypertension would be considered to have an uncontrolled intercurrent illness as diabetes and hypertension - if poorly managed - can lead complications that could interfere with the patient's ability to safely participate in the trial, potentially confounding the study results or posing additional health risks to the patient. * Participants with small-cell carcinoma of the prostate or brain metastasis. * Participants who are not fluent in reading/writing English or Spanish. * Biologic and Pregnant women are excluded from this study because prostate cancer is a disease of biological males. * Participants with implantable cardiac devices. * Participants with limb defects precluding smart-watch wear.

Inclusion Criteria

Exclusion Criteria

* Patients must have histologically or cytologically confirmed adenocarcinoma of prostatic origin without neuroendocrine differentiation or signet ring or small-cell histologic features.
* Patients must be metastatic by having at least one metastatic lesion seen at the time of diagnosis or upon initiation of treatment on bone scan or computed tomography (CT) or magnetic resonance imaging (MRI), or by next-generation molecular imaging (FDG, F-18 sodium fluoride (NaF), C-11 choline, F-18 Fluciclovine, Ga-68 Prostate-specific membrane antigen (PSMA-11) positron emission tomography/computed tomography or magnetic resonance imaging.
* Age ≥ 65years. positron emission tomography the aforementioned GA tools are only validated in those aged 65 and older.
* Planned initiation of intensified hormone deprivation (ADT and ARSI)
* Ability to understand and the willingness to sign a written informed consent document.

* Participants with previous exposure to ADT/ARSI within 12 months of diagnosis, except those who initiated ADT/ARSI within 12 weeks of enrollment.
* Participants who had surgical orchiectomy outside of 12 weeks before their metastatic diagnosis.
* Participants who have had previous chemotherapy for metastatic prostate cancer.
* Uncontrolled intercurrent illness. "Uncontrolled intercurrent illness" refers to a concurrent medical condition that is not adequately managed or stable at the time of enrollment. This could be any illness, disorder, or medical issue occurring alongside the primary disease being treated or studied, and its lack of control poses additional risk to the patient or complicates the management of the primary condition. For example, in the context of enrolling patients in a clinical trial for a cancer treatment, a patient with uncontrolled diabetes mellitus or hypertension would be considered to have an uncontrolled intercurrent illness as diabetes and hypertension - if poorly managed - can lead complications that could interfere with the patient's ability to safely participate in the trial, potentially confounding the study results or posing additional health risks to the patient.
* Participants with small-cell carcinoma of the prostate or brain metastasis.
* Participants who are not fluent in reading/writing English or Spanish.
* Biologic and Pregnant women are excluded from this study because prostate cancer is a disease of biological males.
* Participants with implantable cardiac devices.
* Participants with limb defects precluding smart-watch wear.

Contacts and Locations

Study Contact

Clinical Trials Intake

CONTACT

8557028222

cancerclinicaltrials@bsd.uchicago.edu

Study Locations (Sites)

o University of Chicago Medicine Comprehensive Cancer Center

Chicago, Illinois, 60637

United States

Collaborators and Investigators

Sponsor: University of Chicago

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2026-04

Study Completion Date2031-04

Study Record Updates

Study Start Date2026-04

Study Completion Date2031-04

Terms related to this study

Additional Relevant MeSH Terms

Prostate Cancer
Prostate Cancer Metastatic